NASDAQ:RGNXRegenxbio Stock Price, Forecast & News

Regenxbio's stock was trading at $32.89 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, RGNX stock has increased by 15.8% and is now trading at $38.10. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regenxbio in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Regenxbio.

Regenxbio is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Regenxbio.

Regenxbio Inc (NASDAQ:RGNX) issued its quarterly earnings results on Thursday, May, 7th. The biotechnology company reported ($1.08) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.87) by $0.21. The biotechnology company had revenue of $17.60 million for the quarter, compared to the consensus estimate of $17.99 million. Regenxbio had a negative net margin of 197.23% and a negative return on equity of 27.84%. The company's revenue for the quarter was up 1855.6% compared to the same quarter last year. During the same period last year, the business posted ($0.89) earnings per share. View Regenxbio's earnings history.

6 equities research analysts have issued 12-month price targets for Regenxbio's shares. Their forecasts range from $37.00 to $150.00. On average, they expect Regenxbio's share price to reach $68.33 in the next year. This suggests a possible upside of 79.4% from the stock's current price. View analysts' price targets for Regenxbio.

Press coverage about RGNX stock has been trending somewhat positive recently, according to InfoTrie Sentiment. The research group ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Regenxbio earned a news sentiment score of 0.8 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days. View the latest news about Regenxbio.

Some companies that are related to Regenxbio include Allogene Therapeutics (ALLO), Acceleron Pharma (XLRN), Crispr Therapeutics (CRSP), Novavax (NVAX), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Halozyme Therapeutics (HALO), Ablynx (ABLYF), Momenta Pharmaceuticals (MNTA), Iovance Biotherapeutics (IOVA), bluebird bio (BLUE), Fate Therapeutics (FATE), Denali Therapeutics (DNLI), Twist Bioscience (TWST) and Alector (ALEC). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Regenxbio investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Voyager Therapeutics (VYGR), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Amarin (AMRN), QUALCOMM (QCOM), Bristol-Myers Squibb (BMY) and Square (SQ).

Regenxbio trades on the NASDAQ under the ticker symbol "RGNX."

Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of RGNX stock can currently be purchased for approximately $38.10.

Regenxbio has a market capitalization of $1.42 billion and generates $35.23 million in revenue each year. The biotechnology company earns $-94,730,000.00 in net income (profit) each year or ($3.26) on an earnings per share basis. Regenxbio employs 192 workers across the globe.

The official website for Regenxbio is www.regenxbio.com.

Regenxbio's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-552-8181 or via email at [email protected]